Mazdutide and Retatrutide Interaction: Monitor | Peptide Database

Join others researching Trazodone — share findings, ask questions, and learn from real experiences Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes. Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.

Primary FDA-approved indication for anemia secondary to chronic kidney disease. FDA-approved for treating anemia in cancer patients receiving chemotherapy. Used to reduce need for blood transfusions in certain surgical settings. Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA. May accelerate adaptation to high altitude by increasing red blood cell mass.